Oct 07, 2020 / 04:00PM GMT
Operator
Good afternoon, everyone, and welcome to the AcelRx Virtual KOL Event on Perioperative Use of DSUVIA. I would now like to turn the call over to Vince Angotti, CEO of AcelRx Pharmaceuticals.
Vincent J. Angotti - AcelRx Pharmaceuticals, Inc. - CEO & Director
Thank you, operator. And thanks to all of you for your attendance and interest in AcelRx today, and welcome to our KOL call with Dr. Tvetenstrand and Cassavaugh, who will be sharing their real-world experience and data on the perioperative use of DSUVIA and their perspective on this use. This very recent data has been extremely well-received at advisory boards and other institutions, and we thought it was important to share it with our investor audience as well. While most of you are aware of the DoD's history of interest in DSUVIA and its potential application in the ER setting, today's conference will provide insight into how it is considered by health care practitioners in the surgery setting.
Today's content is strictly focused on the medical aspect of DSUVIA, and out of respect for our
AcelRx Pharmaceuticals, Inc. - Special Call Transcript
Oct 07, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers